Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis
Melanoma frequently develops bone metastases, leading to skeletal-related events and poor survival. The tumor microenvironment (TME) plays a pivotal role in melanoma progression, bone metastasis, and immunotherapy resistance. Key immunosuppressive cells including myeloid-derived suppressor cells (MD...
| 出版年: | Frontiers in Immunology |
|---|---|
| 主要な著者: | , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Frontiers Media S.A.
2025-08-01
|
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1608215/full |
| _version_ | 1849361911666180096 |
|---|---|
| author | Yiqun Ma Lin Zhang Weimin Liu |
| author_facet | Yiqun Ma Lin Zhang Weimin Liu |
| author_sort | Yiqun Ma |
| collection | DOAJ |
| container_title | Frontiers in Immunology |
| description | Melanoma frequently develops bone metastases, leading to skeletal-related events and poor survival. The tumor microenvironment (TME) plays a pivotal role in melanoma progression, bone metastasis, and immunotherapy resistance. Key immunosuppressive cells including myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and cancer-associated fibroblasts (CAFs) promote immune evasion and osteolytic bone destruction via RANKL-dependent and -independent mechanisms. Immune checkpoint inhibitors (ICIs), including anti-CTLA-4 and anti-PD-1/PD-L1 therapies, have revolutionized melanoma treatment, yet resistance remains common due to TME immunosuppression. Emerging strategies, such as combination therapies, aim to enhance efficacy by reshaping the TME. This review synthesizes current knowledge on TME-driven immunosuppression, bone metastasis mechanisms, and immunotherapeutic advancements, offering insights into overcoming resistance and improving patient outcomes. |
| format | Article |
| id | doaj-art-e551291ae84c40d9bef574440df4e1ef |
| institution | Directory of Open Access Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| spelling | doaj-art-e551291ae84c40d9bef574440df4e1ef2025-08-27T05:18:39ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.16082151608215Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasisYiqun Ma0Lin Zhang1Weimin Liu2Department of Burns and Plastic Surgery, Kunming Children′s Hospital, Children′s Hospital Affiliated to Kunming Medical University, Kunming, ChinaDepartment of Orthopaedic, The Third Affiliated Hospital of Shenzhen University (Luohu People’s Hospital), Shenzhen, ChinaDepartment of Dermatology, The Affiliated Hospital of Yunnan University, Kunming, ChinaMelanoma frequently develops bone metastases, leading to skeletal-related events and poor survival. The tumor microenvironment (TME) plays a pivotal role in melanoma progression, bone metastasis, and immunotherapy resistance. Key immunosuppressive cells including myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and cancer-associated fibroblasts (CAFs) promote immune evasion and osteolytic bone destruction via RANKL-dependent and -independent mechanisms. Immune checkpoint inhibitors (ICIs), including anti-CTLA-4 and anti-PD-1/PD-L1 therapies, have revolutionized melanoma treatment, yet resistance remains common due to TME immunosuppression. Emerging strategies, such as combination therapies, aim to enhance efficacy by reshaping the TME. This review synthesizes current knowledge on TME-driven immunosuppression, bone metastasis mechanisms, and immunotherapeutic advancements, offering insights into overcoming resistance and improving patient outcomes.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1608215/fullmelanomabone metastasisosteoclaststumor microenvironmentimmune checkpoint inhibitorsimmunotherapy |
| spellingShingle | Yiqun Ma Lin Zhang Weimin Liu Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis melanoma bone metastasis osteoclasts tumor microenvironment immune checkpoint inhibitors immunotherapy |
| title | Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis |
| title_full | Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis |
| title_fullStr | Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis |
| title_full_unstemmed | Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis |
| title_short | Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis |
| title_sort | immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis |
| topic | melanoma bone metastasis osteoclasts tumor microenvironment immune checkpoint inhibitors immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1608215/full |
| work_keys_str_mv | AT yiqunma immunosuppressivetumormicroenvironmentandadvanceinimmunotherapyinmelanomabonemetastasis AT linzhang immunosuppressivetumormicroenvironmentandadvanceinimmunotherapyinmelanomabonemetastasis AT weiminliu immunosuppressivetumormicroenvironmentandadvanceinimmunotherapyinmelanomabonemetastasis |